Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
151.3 USD | +0.01% | -0.09% | -3.51% |
May. 21 | Nanobiotix to Transfer Phase 3 Head and Neck Cancer Study Sponsorship | MT |
May. 21 | J&J: positive trial for Tremfya in ulcerative colitis | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.51% | 364B | |
+37.78% | 723B | |
+31.80% | 598B | |
+19.94% | 331B | |
+5.14% | 288B | |
+15.72% | 244B | |
+9.77% | 210B | |
-4.87% | 208B | |
+9.32% | 169B | |
-0.80% | 162B |
- Stock Market
- Equities
- JNJ Stock
- News Johnson & Johnson
- Johnson & Johnson Announces $6.48 Billion Plan for Unit to Resolve Ovarian Cancer Talc Claims